Valneva (NASDAQ:VALN) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Valneva (NASDAQ:VALN) in a report released on Tuesday morning, Benzinga reports. They currently have a $26.00 price objective on the stock.

Valneva Trading Down 0.8 %

VALN stock opened at $7.26 on Tuesday. The company has a quick ratio of 2.15, a current ratio of 2.63 and a debt-to-equity ratio of 0.97. Valneva has a twelve month low of $6.39 and a twelve month high of $14.94. The stock has a market capitalization of $505.59 million, a price-to-earnings ratio of -17.71 and a beta of 2.19. The firm’s fifty day simple moving average is $7.37 and its two-hundred day simple moving average is $7.66.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%. The business had revenue of $40.97 million for the quarter, compared to analysts’ expectations of $46.83 million. As a group, analysts anticipate that Valneva will post 0.02 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC lifted its stake in Valneva SE (NASDAQ:VALN) by 42.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,252 shares of the company’s stock after purchasing an additional 26,248 shares during the period. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 at the end of the most recent quarter. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.